SCHEMBL47270

SCHEMBL47270

CC(=O)c1nc2ccccc2nc1O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.54
ALDH1A1 P00352 4/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
MAPK1 P28482 1/20 0.46
CASP1 P29466 1/20 0.46
CASP7 P55210 1/20 0.46
RAB9A P51151 3/20 0.41
KDM4E B2RXH2 2/20 0.41
NPC1 O15118 2/20 0.41
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
PABPC1 P11940 1/20 0.41
HSP90AA1 P07900 1/20 0.41
HSP90AB1 P08238 1/20 0.41
PIM1 P11309 3/20 0.40
HSD17B10 Q99714 2/20 0.40
TP53 P04637 1/20 0.40
LMNA P02545 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
HPGD P15428 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14099196 0.87 MAPT (0.62) MAPTALDH1A1SMN1; SMN2MAPK1CASP1
SCHEMBL42617 0.81 ALDH1A1 (0.75) MAPTALDH1A1SMN1; SMN2RAB9AKDM4E
SCHEMBL13544940 0.80 NQO2 (0.48) MAPTALDH1A1SMN1; SMN2RAB9AKDM4E
SCHEMBL3701892 0.79 TDP1 (0.56) MAPTALDH1A1SMN1; SMN2MAPK1CASP1
SCHEMBL4833903 0.79 MAPT (0.54) MAPTALDH1A1SMN1; SMN2MAPK1CASP1
SCHEMBL6991670 0.79 ALDH1A1 (0.54) MAPTALDH1A1SMN1; SMN2RAB9AKDM4E
SCHEMBL43146 0.79 MAPT (0.54) MAPTALDH1A1SMN1; SMN2RAB9AKDM4E
SCHEMBL23308057 0.79 ALDH1A1 (0.48) MAPTALDH1A1SMN1; SMN2RAB9AKDM4E
SCHEMBL4099973 0.79 ALDH1A1 (0.48) MAPTALDH1A1SMN1; SMN2MAPK1KDM4E
SCHEMBL18680083 0.79 MAPT (0.48) MAPTALDH1A1SMN1; SMN2MAPK1CASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11780863-B2 Quinone methide analog signal amplification VENTANA MEDICAL SYSTEMS, INC. (US) 2023-10-10 US disclosed
US-20220155312-A1 APPLICATION OF CLICK CHEMISTRY FOR SIGNAL AMPLIFICATION IN IHC AND ISH ASSAYS VENTANA MED SYST INC (US) 2022-05-19 US disclosed
EP-3492919-A2 QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION Ventana Medical Systems, Inc. (US) 2019-06-05 EP disclosed
US-20190127405-A1 QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION VENTANA MED SYST INC (US) 2019-05-02 US disclosed
US-10168336-B2 Quinone methide analog signal amplification VENTANA MEDICAL SYSTEMS, INC. (US) 2019-01-01 US disclosed
US-20170089911-A1 QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION VENTANA MEDICAL SYSTEMS, INC. 2017-03-30 US disclosed
WO-2015124703-A1 QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION VENTANA MEDICAL SYSTEMS, INC. (US) 2015-08-27 WO disclosed
US-8846320-B2 Haptens, hapten conjugates, compositions thereof and method for their preparation and use VENTANA MEDICAL SYSTEMS, INC. (US) 2014-09-30 US disclosed
WO-2012003476-A2 HAPTEN CONJUGATES FOR TARGET DETECTION VENTANA MEDICAL SYSTEMS, INC. (US) 2012-01-05 WO disclosed
US-7829564-B2 α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors G.D. SEARLE LLC (US) 2010-11-09 US disclosed
US-7695929-B2 Derivatives containing oxazole, pyrazole, thiazole, nitroaryl compound, benzofurazan, triterpene, urea, thiourea, rotenoid, coumarin or cyclolignan such as 4-(2-hydroxyphenyl)-1H-benzo[b][1,4]diazepine-2(3H)-one; multiplexed diagnostic assay for multiple targets in sample; antibodies; kits VENTANA MEDICAL SYSTEMS, INC. (US) 2010-04-13 US disclosed
US-7645771-B2 CCR5 antagonists as therapeutic agents SMITHKLINE BEECHAM CORP. (US) 2010-01-12 US disclosed
US-7645771-B2 CCR5 antagonists as therapeutic agents SMITHKLINE BEECHAM CORP. (US) 2010-01-12 US disclosed
US-20090023664-A1 ALPHA- AND BETA-AMINO ACID HYDROXYETHYLAMINO SULFONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS G.D. SEARLE LLC (US) 2009-01-22 US disclosed
US-7250389-B1 Antifungal compound and process for producing the same MEIJI SEIKA KAISHA, LTD. (JP) 2007-07-31 US disclosed
US-7250389-B1 Antifungal compound and process for producing the same MEIJI SEIKA KAISHA, LTD. (JP) 2007-07-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190127405-A1 QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION NQO2, SQOR, MRM1 MAPT 4787/4885ALDH1A1 208/4885SMN1; SMN2 3661/4885
US-20090023664-A1 ALPHA- AND BETA-AMINO ACID HYDROXYETHYLAMINO SULFONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS DNPEP, ASPH, PREP MAPT 2279/4885ALDH1A1 1555/4885SMN1; SMN2 2396/4885
US-11780863-B2 Quinone methide analog signal amplification NQO2, SQOR, MRM1 MAPT 4787/4885ALDH1A1 208/4885SMN1; SMN2 3661/4885
US-20170089911-A1 QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION NQO2, SQOR, MRM1 MAPT 4787/4885ALDH1A1 208/4885SMN1; SMN2 3661/4885
US-10168336-B2 Quinone methide analog signal amplification NQO2, SQOR, MRM1 MAPT 4787/4885ALDH1A1 208/4885SMN1; SMN2 3661/4885
US-20220155312-A1 APPLICATION OF CLICK CHEMISTRY FOR SIGNAL AMPLIFICATION IN IHC AND ISH ASSAYS MKI67, TIE1, ALK MAPT 4162/4885ALDH1A1 37/4885SMN1; SMN2 4575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.